

# David W Piotrowski

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4626258/publications.pdf>

Version: 2024-02-01

42  
papers

1,120  
citations

361413

20  
h-index

414414

32  
g-index

46  
all docs

46  
docs citations

46  
times ranked

1434  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8208-8226.	6.4	42
2	PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 326-342.	6.4	29
3	PF-07059013: A noncovalent hemoglobin modulator favorably impacts disease state in a mouse model of sickle cell disease. <i>American Journal of Hematology</i> , 2021, 96, E272-E275.	4.1	5
4	Acylative Dynamic Kinetic Resolution of Secondary Alcohols: Tandem Catalysis by HyperBTM and Bäckvall's Ruthenium Complex. <i>Journal of Organic Chemistry</i> , 2021, 86, 7189-7202.	3.2	12
5	Merging C(sp <sup>3</sup> )-H activation with DNA-encoding. <i>Chemical Science</i> , 2020, 11, 12282-12288.	7.4	57
6	RASS-Enabled S/P <sup>α</sup> C and S <sup>α</sup> N Bond Formation for DEL Synthesis. <i>Angewandte Chemie</i> , 2020, 132, 7447-7453.	2.0	9
7	RASS-Enabled S/P <sup>α</sup> C and S <sup>α</sup> N Bond Formation for DEL Synthesis. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 7377-7383.	13.8	44
8	Discovery and Early Development of Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors. <i>ACS Symposium Series</i> , 2019, , 267-296.	0.5	0
9	Expanding Reactivity in DNA-Encoded Library Synthesis via Reversible Binding of DNA to an Inert Quaternary Ammonium Support. <i>Journal of the American Chemical Society</i> , 2019, 141, 9998-10006.	13.7	119
10	Overcoming the Challenges of Making a Single Enantiomer N-1 Substituted Tetrazole Prodrug Using a Tin-Mediated Alkylation and Enzymatic Resolution. <i>Organic Process Research and Development</i> , 2019, 23, 1167-1177.	2.7	9
11	A Novel Non-Covalent Modulator of Hemoglobin Improves Anemia and Reduces Sickling in a Mouse Model of Sickle Cell Disease. <i>Blood</i> , 2019, 134, 207-207.	1.4	0
12	Discovery of a Novel Small-Molecule Modulator of CX <sub>2</sub> C Chemokine Receptor Type 7 as a Treatment for Cardiac Fibrosis. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 3685-3696.	6.4	18
13	Identification of Morpholino-2-H-pyrido[3,2-b][1,4]oxazin-3(4-H)-ones as Nonsteroidal Mineralocorticoid Antagonists. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1086-1097.	6.4	15
14	Deuterium isotope effects in drug pharmacokinetics II: Substrate-dependence of the reaction mechanism influences outcome for cytochrome P450 cleared drugs. <i>PLoS ONE</i> , 2018, 13, e0206279.	2.5	19
15	Discovery of N-(piperidin-3-yl)-N-(pyridin-2-yl)piperidine/piperazine-1-carboxamides as small molecule inhibitors of PCSK9. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 3685-3688.	2.2	11
16	Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5704-5718.	6.4	37
17	Development of a Chiral DMAP Catalyst for the Dynamic Kinetic Resolution of Azole Hemiaminals. <i>Journal of Organic Chemistry</i> , 2017, 82, 869-886.	3.2	28
18	Liver-Targeted Small-Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 16218-16222.	13.8	35

#	ARTICLE	IF	CITATIONS
19	A Scalable Route for the Regio- and Enantioselective Preparation of a Tetrazole Prodrug: Application to the Multi-Gram-Scale Synthesis of a PCSK9 Inhibitor. <i>Organic Process Research and Development</i> , 2017, 21, 1990-2000.	2.7	20
20	Liver-Targeted Small-Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis. <i>Angewandte Chemie</i> , 2017, 129, 16436-16440.	2.0	1
21	Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain. <i>PLoS Biology</i> , 2017, 15, e2001882.	5.6	104
22	Regio- and Enantioselective Synthesis of Azole Hemiaminal Esters by Lewis Base Catalyzed Dynamic Kinetic Resolution. <i>Journal of the American Chemical Society</i> , 2016, 138, 4818-4823.	13.7	59
23	Synthesis and Analysis of Macrocyclic Peptides with 310-Helical Structure. <i>Synlett</i> , 2015, 26, 1164-1168.	1.8	2
24	Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4080-4085.	6.4	38
25	Identification of (<i>R</i>)-6-(1-(4-Cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1<i>H</i>-pyrazol-3-yl)-2-methoxynicotinic Acid, a Highly Potent and Selective Nonsteroidal Mineralocorticoid Receptor Antagonist. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 4273-4288.	6.4	22
26	Regioselective Hydroarylations and Parallel Kinetic Resolution of Vince Lactam. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 10607-10610.	13.8	21
27	Identification of Tetrahydropyrido[4,3- <i>d</i> ]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 Agonists. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 63-68.	2.8	45
28	Optimization of triazole-based TGR5 agonists towards orally available agents. <i>MedChemComm</i> , 2013, 4, 205-210.	3.4	25
29	Stereodefined Cyclopentanes by Hydroarylation-Ring Opening. <i>Synthetic Communications</i> , 2013, 43, 1007-1015.	2.1	4
30	Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 6239-6242.	2.2	10
31	Synthesis of a <i>cis</i> 2,5-Disubstituted Morpholine by De-epimerization: Application to the Multigram Scale Synthesis of a Mineralocorticoid Antagonist. <i>Organic Process Research and Development</i> , 2013, 17, 934-939.	2.7	10
32	Rapid and Selective in situ Reduction of Pyridine-N-oxides with Tetrahydroxydiboron. <i>Synlett</i> , 2013, 24, 2695-2700.	1.8	30
33	Metabolism, Excretion, and Pharmacokinetics of		

#	ARTICLE	IF	CITATIONS
37	The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism. <i>Journal of Translational Medicine</i> , 2011, 9, 180.	4.4	45
38	1-((3S,4S)-4-Amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 1810-1814.	2.2	20
39	Hydroarylation of 2-azabicyclohept-5-en-3-one. <i>Tetrahedron Letters</i> , 2010, 51, 17-19.	1.4	16
40	A convenient and rapid approach for the synthesis of 1-benzyl-3-heterocyclic pyrazoles. <i>Tetrahedron Letters</i> , 2009, 50, 5479-5481.	1.4	9
41			